Hims & Hers Health Inc. soared after Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply ...

Shares of Hims & Hers Health, Inc. (HIMS) marked their best session in nearly three months on Tuesday, surging over 23% after ...

Hims & Hers Health (NYSE: HIMS) stock surged 23% on Tuesday, April 29, after Novo Nordisk announced plans to offer popular ...

Novo Nordisk, the maker of Wegovy, announced exclusively on " Good Morning America " Tuesday that the medication will soon be available for purchase through the telehealth companies Ro, Hims and ...

Pharma giant Novo Nordisk is partnering with telehealth companies to expand access to its blockbuster weight loss drug Wegovy ...

The pharmaceutical company announced it would be partnering with Hims & Hers., LifeMD and Ro. to provide all five dose strengths of its weight-loss GLP-1 medication Wegovy at a reduced cost of $499.

Shares of Hims & Hers Health ( HIMS -5.48%) and LifeMD ( LFMD -14.33%) are surging on Tuesday. The companie' stocks had ...

70. Novo Nordisk is expanding its efforts to sell its obesity drug Wegovy directly to patients, striking agreements with telehealth companies including Hims & Hers, Ro, and LifeMD. Novo last month ...

Novo Nordisk is expanding access to its GLP-1 drug Wegovy via telehealth, partnering with Hims and Hers, Ro, and LifeMD.

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...

Novo Nordisk is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy ...